Call for Survey Participants: Drug Safety and Pharmacovigilance Teams Subject of Study by Cutting Edge Information

RESEARCH TRIANGLE PARK, NC--(Marketwire - January 25, 2010) - Drug safety and pharmacovigilance teams are facing increasing pressure to identify potential issues that could arise from the use of their companies' medications. If products reach market and have safety issues, the results can be devastating. Often, drugs pulled off the pharmacy shelves die altogether. For the companies whose products do survive safety issues, overall sales rarely come close to initial projections.

Knowing the potential for disaster, companies want their drug safety teams to seek out and identify risks as they happen -- and often before they happen. Many pharmacovigilance groups are using signaling to identify and test for problems that might arise based on similar treatments on the market or in testing. Needless to say, drug safety teams are more important than ever.

As part of Cutting Edge Information's ( growing focus on clinical research, the North Carolina-based research company is investigating the transformation of pharmacovigilance teams as they work to meet growing internal and external demands.

Interested individuals may participate in the study here:

Beyond general pharmacovigilance activities, CEI has highlighted the following categories for more in-depth research:

--  New models for tracking and analyzing adverse events
--  Flow of adverse events into drug safety and out to regulatory
--  Team budgets and staffing resources
--  Outsourcing pharmacovigilance activities
--  Global differences in pharmacovigilance policies and strategies
--  Communicating the value of pharmacovigilance to internal stakeholders

"Pharmacovigilance and drug safety groups are more important than ever," said David Richardson, study lead and research team leader at Cutting Edge Information. "We want to uncover how these groups are evolving to meet the increasing scrutiny and demands placed upon them, both internally and externally."

To participate in Cutting Edge Information's study on pharmacovigilance, visit Survey results from the completed study will be provided for each individual's contribution.

Contact Information: CONTACT: Stephanie Swanson (919) 433-0212